How to buy I-Mab stock

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 378 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

I-Mab stock price (NASDAQ: IMAB)

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

• Key figures

Information last updated 2022-07-02.

Latest market close	$11.49
52-week range	$8.05 - $81.47
50-day moving average more info button	$11.19
200-day moving average more info button	$34.86
Wall St. target price	$76.67
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-4.57

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab price performance over time

Historical closes compared with the close of $11.49 from 2022-07-01

1 week (2022-06-24)	-6.96%
1 month (2022-06-02)	35.34%
3 months (2022-04-01)	-34.38%
6 months (2021-12-31)	-75.75%

1 year (2021-07-02)	-85.93%
2 years (2020-07-02)	-60.81%
3 years (2019-06-28)	N/A
5 years (2017-06-28)	N/A

I-Mab financials

Revenue TTM	$88 million
Gross profit TTM	$41.6 million
Return on assets TTM	-21.69%
Return on equity TTM	-45.78%
Profit margin	0%
Book value	$57.05
Market capitalisation more info button	$949.6 million

TTM: trailing 12 months

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab share price volatility

Over the last 12 months, I-Mab's shares have ranged in value from as little as $8.05 up to $81.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while I-Mab's is 1.0499. This would suggest that I-Mab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd. ; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Frequently asked questions

What percentage of I-Mab is owned by insiders or institutions?
Currently 1.074% of I-Mab shares are held by insiders and 64.043% by institutions. How many people work for I-Mab?
Latest data suggests 378 work at I-Mab. When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December. Where is I-Mab based?
I-Mab's address is: New Bund Center, Shanghai, China, 200124 What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030 What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103